(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 vannual meeting’s prostate cancer session included a presentation by Dr. Dana Rathkopf discussing the trial concept and design of SAABR, a single arm phase 2 study of abiraterone + atezolizumab + GnRH analog with stereo body radiotherapy (SBRT) in men with metastatic hormone sensitive prostate cancer (mHSPC). Several phase 3 trials have demonstrated that adding the androgen synthesis inhibitor abiraterone acetate to androgen deprivation therapy (ADT) offers a survival benefit for men with mHSPC. Furthermore: